Wright, MicroPort Deal Signals Shifts In Global Ortho Industry With China In Focus
This article was originally published in PharmAsia News
Wright, by selling its hip-and-knee reconstruction business, is abandoning the stagnant U.S. large-joint sector, choosing instead to tie its future to the faster growing extremities market. Shanghai-based MicroPort, meanwhile, is looking to compete in China’s growing large-joint market.
You may also be interested in...
Orthopedic companies now target the so-called extremities as an area of capable of producing double-digit growth in sales. To be sure, the markets are considerably smaller than hips or knees, but multinational leaders can’t ignore untapped potential when their core markets are stagnant, and a new front is forming in the battle for foot and ankle supremacy around an old but still underutilized device – total ankle replacement implants.
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.